Activation of downstream epidermal growth factor receptor (EGFR) signaling provides gefitinib-resistance in cells carrying EGFR mutation (Q40176065)

18 September 2017

Activation of downstream epidermal growth factor receptor (EGFR) signaling provides gefitinib-resistance in cells carrying EGFR mutation (English)

1 reference

18 September 2017

11

Mitsune Tanimoto

1 reference

18 September 2017

10

Katsuyuki Kiura

1 reference

18 September 2017

4

Atsuko Ogino

1 reference

18 September 2017

7

Nagio Takigawa

1 reference

18 September 2017

6

Shinichi Toyooka

1 reference

18 September 2017

9

Minoru Takata

1 reference

18 September 2017

3

Hiroyuki Kitao

1 reference

18 September 2017

2

Seiki Hirano

1 reference

18 September 2017

Akiko Uchida

1

1 reference

PubMed ID

17270025

18 September 2017

Kanmei Rai

series ordinal

5

1 reference

PubMed ID

17270025

18 September 2017

Masahiro Tabata

series ordinal

8

1 reference

18 September 2017

1 March 2007

1 reference

18 September 2017

1 reference

18 September 2017

98

1 reference

18 September 2017

3

1 reference

18 September 2017

357-363

1 reference

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

18 September 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00387.X

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00387.X

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00387.X

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00387.X

Erlotinib in lung cancer - molecular and clinical predictors of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00387.X

Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00387.X

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00387.X

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00387.X

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00387.X

Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00387.X

Gefitinib--a novel targeted approach to treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00387.X

Cancer. Addiction to oncogenes--the Achilles heal of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00387.X

The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00387.X

Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00387.X

A small molecule-kinase interaction map for clinical kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00387.X

Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00387.X

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00387.X

EGFR inhibition in non-small cell lung cancer: resistance, once again, rears its ugly head

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00387.X

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00387.X

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00387.X

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00387.X

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00387.X

Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00387.X

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00387.X

HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00387.X

High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00387.X

Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00387.X

ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00387.X

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00387.X

Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00387.X

Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00387.X

Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00387.X

Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00387.X

Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00387.X

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00387.X

Epithelial membrane protein-1 is a biomarker of gefitinib resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00387.X

Cell cycle-dependent activation of Ras.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00387.X

Coordinating ERK/MAPK signalling through scaffolds and inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00387.X

Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00387.X

Cancer genes and the pathways they control

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00387.X

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00387.X

Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00387.X

PI3K/Akt and apoptosis: size matters

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00387.X

The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00387.X

Phosphorylation of Par-4 by protein kinase A is critical for apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00387.X

Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00387.X

10.1111/J.1349-7006.2007.00387.X

21 January 2018

Identifiers

DOI

1 reference

18 September 2017

1 reference

PubMed ID

17270025